Top Markets
#1 Status Status +17.68%
#2 Hex Trust USD Hex Trust USD +4.50%
#3 Bitway Bitway +4.24%
#4 MANTRA MANTRA +3.79%
#5 龙虾 (Lobster) 龙虾 (Lobster) +3.74%
#6 ThunderCore ThunderCore +3.62%
#7 Civic Civic +2.86%
#8 Infinity Ground Infinity Ground +2.69%
#9 MemeCore MemeCore +2.66%
#10 Electroneum Electroneum +2.59%
Coin of the day
Status Status
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Pozycja w akcjach #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Cena akcji
$451.59
Kapitalizacja rynkowa
$114.70B
Zmiana (1 dzień)
-2.36%
Zmiana (1 rok)
-11.89%
Kraj
US
Handel Vertex Pharmaceuticals Incorporated (VRTX)

Kategoria

Healthcare
Wskaźnik P/S dla Vertex Pharmaceuticals Incorporated (VRTX)
Wskaźnik P/S na dzień March 2026 TTM: 9.90
Według najnowszych raportów finansowych i ceny akcji Vertex Pharmaceuticals Incorporated, obecny wskaźnik P/S (TTM) wynosi 9.90. Na koniec 2023 wynosił 10.62.
Historia wskaźnika P/S dla Vertex Pharmaceuticals Incorporated od 2000 do 2026
Wskaźnik P/S na koniec każdego roku
Rok Wskaźnik P/S Zmień
2026 (TTM) 9.90 5.24%
2024 9.41 -11.43%
2023 10.62 28.30%
2022 8.28 10.84%
2021 7.47 -24.50%
2020 9.90 -26.71%
2019 13.50 -2.34%
2018 13.83 -7.73%
2017 14.99 42.14%
2016 10.54 -64.09%
2015 29.36 -38.95%
2014 48.08 248.85%
2013 13.78 137.01%
2012 5.82 20.56%
2011 4.82 -90.15%
2010 48.96 -32.70%
2009 72.75 199.01%
2008 24.33 61.60%
2007 15.06 -23.11%
2006 19.58 27.59%
2005 15.35 89.82%
2004 8.09 -29.86%
2003 11.53 54.66%
2002 7.45 -31.82%
2001 10.93 -82.35%
2000 61.94 0.00%
Wskaźnik P/S dla podobnych firm lub konkurentów
Firma Wskaźnik P/S Różnica wskaźnika P/S Kraj
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.55 -64.14%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.40 -45.44%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.14 -38.02%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.04 -69.26%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.90 30.24%
NL